Home › Funds › ACT CAPITAL MANAGEMENT, LLC › TGTX
ACT CAPITAL MANAGEMENT, LLC position in TGTX
TG THERAPEUTICS · Health Care
ACT CAPITAL MANAGEMENT, LLC reported holding 251,025 shares of TGTX (TG THERAPEUTICS) in its Q2 2026 13F filing — a position valued at US$13.8M, representing 9.01% of its reported portfolio and ranking #2 among its reported holdings. ACT CAPITAL MANAGEMENT, LLC has disclosed TGTX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ACT CAPITAL MANAGEMENT, LLC's TGTX position evolved
ACT CAPITAL MANAGEMENT, LLC first disclosed a stake in TGTX in Q4 2025 at 268,875 shares (US$8.0M). The position peaked in Q2 2026 at 251,025 shares, worth US$13.8M. Across 3 filings, ACT CAPITAL MANAGEMENT, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 251,025 shares valued at US$13.8M — an increase of 2,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 268.88K | $8.02M | New |
| Q1 2026 | 249.03K | $8.27M | Reduce |
| Q2 2026 | 251.03K | $13.79M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TGTX and 13F data
TGTX (TG THERAPEUTICS) is a Health Care company. 53 other funds we track also report a position in TGTX — the largest reported positions include Soleus Capital Management, L.P. (US$160.9M), CONGRESS ASSET MANAGEMENT CO (US$145.4M), Penn Capital Management Company, LLC (US$29.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TGTX
- Soleus Capital Management, L.P. 2.93M sh · $160.86M · Q2 2026
- CONGRESS ASSET MANAGEMENT CO 2.61M sh · $145.39M · Q3 2026
- Penn Capital Management Company, LLC 536.07K sh · $29.51M · Q2 2026
- Opaleye Management Inc. 535.00K sh · $29.39M · Q2 2026
- Occam Crest Management LP 425.00K sh · $22.73M · Q2 2026
- 683 Capital Management, LLC 389.08K sh · $21.38M · Q2 2026
More on ACT CAPITAL MANAGEMENT, LLC
FAQ
How long has ACT CAPITAL MANAGEMENT, LLC held TGTX?
ACT CAPITAL MANAGEMENT, LLC has disclosed TGTX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is ACT CAPITAL MANAGEMENT, LLC's current position in TGTX?
As of Q2 2026, ACT CAPITAL MANAGEMENT, LLC holds 251.03K shares of TGTX (TG THERAPEUTICS), valued at $13.79M, representing 9.01% of its reported portfolio and ranking #2.
Has ACT CAPITAL MANAGEMENT, LLC been buying or selling TGTX?
In the latest 13F filing (Q2 2026), ACT CAPITAL MANAGEMENT, LLC increased its position in TGTX. The position peaked in Q2 2026 at 251.03K shares.
Which other funds hold TGTX?
Other major institutional holders of TGTX include Soleus Capital Management, L.P., CONGRESS ASSET MANAGEMENT CO, Penn Capital Management Company, LLC, among 53 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.